Drugs / RESP301
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06041919 | Sep 2023 → Jul 2024 | pulmonary tuberculosis | Thirty Respiratory Limited | Terminated | No outcome recorded |
| Phase 2 | NCT05101915 | Nov 2021 → Jan 2024 | cystic fibrosis | Papworth Hospital NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 2 | NCT04858451 | Mar 2021 → Dec 2022 | bronchiectasis | Thirty Respiratory Limited | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04460183 | Jul 2020 → Apr 2021 | COVID-19 | Thirty Respiratory Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RESP301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05101915 ↗ |
| Modality | Other / unclassified | “RESP301, a Nitric Oxide generating solution” NCT04460183 ↗ |
| Route | Inhaled | “Participants will receive inhaled RESP301 administered using a nebulizer three times a day for up to 10 days in addition to the standard of care.” NCT04460183 ↗ |